Delivery Order SPE2DB22D9316-SPE2DB24FYP81

Award Date 7/29/24
Potential Completion Date 8/19/24
Potential Value $56K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $16,057.14, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order for the supply of Keytruda 100 mg/4 ml vial, with an ultimate completion date of November 5, 2024. DMS Pharmaceutical Group Inc. holds a significant indefinite delivery contract (IDC) with the DLA under the SPE2DB program,...
This federal contract award, valued at $81,895.60, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order for the supply of 4,567,379,133 units of Keytruda 100 mg/4 mL vial (4 mL). This award is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group Inc. with the DLA under the SPE2DB program,...
This federal contract award was issued by the Defense Logistics Agency (DLA), a defense agency, to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $40,109.20, is a firm fixed-price delivery order for Keytruda 100 mg/4 ml vials. This order is part of a larger indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA, valued at up to $499,999,999, that runs through December 31,...
This federal contract award was issued by the Defense Logistics Agency (DLA), a defense agency, to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $120,327.60 firm fixed-price delivery order contract is for the supply of Keytruda 100 mg/4 ml vials. The contract has an ultimate completion date of December 30, 2024. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under...
This federal contract award, valued at $40,142.85, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order for the supply of Keytruda 100 mg/4 ml vial, a cancer treatment drug, with an ultimate completion date of October 17, 2024. DMS Pharmaceutical Group Inc. holds a significant indefinite delivery contract (IDC) with the DLA under...
This federal contract award, valued at $160,571.40, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order for the supply of KEYTRUDA 100 MG/4 ML VIAL 4ML, with an ultimate completion date of August 12, 2024. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $48,131.04 contract is to provide Keytruda 100 mg/4 ml vials to support the recurring medical supply needs of military health facilities. This delivery order is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS Pharmaceutical Group holds with...
This is a federal contract award by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $96,342.84, is a firm fixed-price delivery order for the supply of Keytruda 100 mg/4 ml vials. The award is issued under a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group, valued up to $499,999,999, that runs through December 31, 2025. This single-award IDC,...
This federal contract award, valued at $80,285.70, was issued to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a delivery order under a larger indefinite delivery contract (IDC) with the Defense Logistics Agency (DLA) valued up to $499,999,999, which runs through December 31, 2025. The contract is for the delivery of Keytruda 100 mg/4 ml vial, a specialized oncology medication, to support the recurring medical...
This federal contract award was made by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $46,536.96 firm fixed-price delivery order is for the supply of Keytruda 100 mg/4 ml vial, with an ultimate completion date of October 7, 2024. The contract is part of a larger $499,999,999 indefinite delivery contract (IDC) under the DLA's SPE2DB program, which allows the DLA to issue firm...
  • SPE2DB22D9316
    Indefinite Delivery Contract
  • SPE2DB22D9316-SPE2DB24FYP81
    Delivery Order

This federal contract award, valued at $56,012.64, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order for the supply of Keytruda 100 mg/4 ml vials, with an ultimate completion date of August 19, 2024.

DMS Pharmaceutical Group Inc. holds a larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which allows the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to support the medical supply needs of military health facilities worldwide. This contract complements the company's separate prime vendor contracts for direct distribution of prescription drugs and pharmacy services to Department of Defense (DoD) sites, solidifying its position as a crucial supplier in the federal pharmaceutical supply chain. The contract does not have a set-aside designation.

Generated 10/28/24, 9:44 AM